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The cAMP-responsive element modulator alpha (CREMα) plays a role in autoimmunity 
and, in particular, in systemic lupus erythematosus. CREMα negatively regulates IL-2 
transcription and activates IL-17 expression by direct transcriptional mechanisms. To 
understand the role of CREM in autoimmunity, we recently generated a mouse with a 
transgenic overexpression of CREMα selectively in T cells. This mouse is characterized 
by enhanced IL-17 and IL-21 expression. We, herein, dissect the transcriptional mech-
anisms of enhanced IL-21 transcription in these mice. T cells of CREMα transgenic 
mice display an enhanced binding of CREMα to the CD3ζ chain promoter resulting 
in decreased CD3ζ chain expression. This is accompanied by a decreased excitation 
threshold and enhanced Ca2+ influx, which is known to induce IL-21 expression via 
NFATc2 activation. However, CREMα directly binds to cAMP-response element (CRE) 
half-site within the Il-21 promoter, which results in enhanced promoter activity shown by 
promoter reporter assays. CREMα-induced IL-21 transcription is not abrogated in the 
presence of cyclosporine A but depends on an intact CRE site within the IL-21 promoter, 
which suggests that CREM largely enhances IL-21 expression by direct transcriptional 
regulation. IL-21 transcription is critical for IL-17 generation in these mice, since IL-21 
receptor blockade downregulates IL-17 transcription to wild-type levels. Finally, this is 
of functional relevance since CREMα transgenic mice display enhanced disease activity 
in dextran sodium sulfate-induced colitis accompanied by higher local IL-21 expression. 
Thus, we describe two novel mechanisms of CREMα-dependent IL-21 transcription. 
Since T cells of systemic lupus erythematosus patients are characterized by enhanced 
IL-21 transcription, this might also be of functional relevance in humans.
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inTrODUcTiOn
cAMP-responsive element modulator (CREM) is a member of the ATF/CREB type bZip tran-
scription factors family. cAMP activates proteinkinase A that phosphorylates and thus activates 
CREB and CREM. Members of the ATF/CREB family bind to the cAMP-response element (CRE) 
in the promoter regions of target genes. This binding results in either suppression or activation 
Abbreviations: CREM, cAMP-responsive element modulator; CSA, cyclosporine A; DSS, dextran sodium sulfate; Il-21-luc, 
IL-21 promoter luciferase plasmid; mLN, mesenterial lymph node; NP-CGG, 4-hydroxy-3-nitrophenylacetyl chicken gamma 
globulin; P/I, Phorbol-12-myristat-13-acetat/ionomycin.
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of promoter activity, and, respectively, of gene expression (1, 
2). CREMα, a CREM isoform generated by alternative splic-
ing, has key functions as an epigenetic and transcriptional 
regulator of cytokine expression in T cells from systemic lupus 
erythematosus (SLE) patients (3). T cells from patients with 
SLE exhibit CREMα overexpression (4). CREMα contributes 
to silencing of IL2 in these cells through transrepression and 
tissue- and region-specific recruitment of specific DNA and 
histone methyltransferases or HDACs (5). In addition, CREMα 
transactivates IL17a promoters, which suggests that CREMα 
contributes to increased IL17a mRNA expression and IL17a 
protein levels in SLE patients (6). Notably, the observed effects 
of CREMα on IL-2 and IL-17a cytokine production in humans 
are also observed in transgenic mice with T cell-specific 
CREMα overexpression (under control of the cd2 promoter) 
[CREMα transgenic (tg)] (7). These mice have decreased IL-2 
and increased IL-17a levels and are more prone to develop 
signs of autoimmunity (including lymphadenopathy and 
higher autoantibody titers against double-stranded DNA) 
when an additional genetic deletion of the cd95 gene (Fas) is 
present (7, 8).
IL-21 is a type I cytokine, which exerts critical roles in 
immune cell differentiation and function by signaling through 
a heterodimeric receptor, which is formed by common gamma 
chain (shared with IL-2, IL-4, IL-7, IL-9, IL-13, and IL-15 
receptors) and an IL-21-specific receptor (IL-21R) (9, 10). Since 
IL-21R is expressed on CD4+, CD8+ T cells, B cells, NK cells, 
dendritic cells, macrophages, and also non-immune cells (e.g., 
fibroblasts, epithelial cells, and keratinocytes) (10, 11), IL-21 
regulates multiple cell types during the course of inflammatory 
responses. IL-21 is produced by activated (NK) T cells and by dif-
ferentiated CD4+ T cell subsets (12). Of those, Th17 cells are the 
main producer of IL-21 in mice (13, 14) and IL-21 plays a key role 
in the amplification of Th17 cell responses (13). Furthermore, 
IL-21 is produced by and plays a role in development of follicular 
T helper cells by inducing Bcl-6 expression (15, 16). In B cells, 
IL-21 promotes plasma cell differentiation (17–19). With regard 
to other T cell subsets, IL-21 suppresses the differentiation and 
functions of Th2 cells (20) and negatively regulates induced 
regulatory T cells as IL-21 antagonizes TGF-β1-mediated induc-
tion of FoxP3-expressing T cell (13, 21). Moreover, IL-21 renders 
human CD4+CD25− T cells resistant to the suppressive effects of 
regulatory T cells (22).
Expression of IL-21 is strictly calcium dependent, which 
is mediated by NFATc2 binding to the IL-21 promoter region 
(23). NFAT activation is induced by calcium signaling as NFAT 
proteins are activated via phosphorylation by the by calcium/
calmodulin-dependent phosphate calcineurin, thereby translo-
cating NFAT proteins from the cytoplasm to the nucleus (24). 
The central role of NFAT for TCR-stimulated Il-21 promoter 
activity was further confirmed by Mehta et  al. (25). However, 
IL-21 is still expressed in NFATc2-deficient mice, implying that 
additional transcription factors are be involved in the regulatory 
events of il21 gene expression (23). One of these transcription 
factors is c-Rel. This member of the NFκB transcription factor 
family activates IL-21 expression via a binding site in the proxi-
mal Il-21 promoter (26).
IL-21 is overproduced in many chronic inflammatory disor-
ders, including inflammatory bowel diseases (IBD), rheumatoid 
arthritis, and SLE (9, 27, 28). In addition, blockade of IL-21 
or IL21R has therapeutic effects on various murine models of 
inflammation and autoimmunity (11). Particulary, the role of 
IL-21 in IBD is well established. IL-21 modulates the activity of 
several cell types that contribute to tissue damage in IBD. With 
this regard, it is not surprising that mice lacking IL-21 are unable 
to upregulate Th17-associated molecules during experimental 
gut inflammation and are largely protected against chemically 
induced colitis (29, 30). IBD are chronic, relapsing inflamma-
tory disorders of the gastrointestinal tract and involve multiple 
pathogenic factors including environmental changes, genetical 
predispositions, an abnormal gut microbiota, and a broadly dys-
regulated immune response (31). Current studies indicate that an 
active and dynamic interplay between immune and non-immune 
cells and gut microbiota play a major role in this pathologic pro-
cess, and that cytokines, such as IL-21, are essential mediators of 
this crosstalk.
Previously, we have shown that that mice with a T cell-specific 
overexpression of CREMα show – beyond enhanced expression 
of IL-17a and decreased expression of IL-2 – also an enhanced 
IL-21 production both in vitro after T cell stimulation with anti 
CD3 and CD28 and in  vivo in a contact dermatitis model (7). 
We, therefore, aimed to analyze molecular mechanisms of IL-21 
transcription in these mice. Moreover, by a comparative analysis 
of CREMα and wild-type (WT) mice in an experimental colitis 
model, which is associated with T cellular IL-21 production, we 




Experiments were performed with age-matched FVB WT and 
CREMα tg FVB mice (7, 32) All mice were bred in our animal facil-
ity and kept under standardized conditions. Animals were housed 
in the same rooms under pathogen-free and helicobacter-free 
conditions. The study was approved by the regional government 
authorities and animal procedures were performed according 
to German legislation for animal protection. Permission for the 
projects has been granted by the Regierungspräsident/LANUV 
Nordrhein-Westfalen.
In Vitro T cell stimulation
T cells were obtained from spleens of WT and CREMα tg mice 
by negative isolation using magnetic cell separation via CD4+ 
MACS Kits (Miltenyi, Germany) according to manufacturer’s 
instructions. Cells were cultured in RPMI medium supplemented 
with 1% penicillin/streptomycin and 10% inactivated fetal calf 
serum (Gibco Life Technologies, Germany) in individual wells of 
96-well round-bottom microtiter plates. T cells were stimulated 
with anti-CD3 and anti-CD28 antibodies (both at 3 μg/ml; BD 
Bioscience, Germany) or with PMA (20  nM) and ionomycin 
(2 μM) (both Sigma-Aldrich, USA) as indicated.
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[ca2+]i Measurement
Freshly isolated T lymphocytes (5 × 106 cells/ml) were washed in 
phosphate-buffered saline (PBS), resuspended in RPMI contain-
ing 1% bovine serum albumin (BSA), and incubated for 40 min at 
37°C with 1.3 μM Fluo-3-AM and 2.75 μM Fura-Red-AM (both 
from Invitrogen) in the presence of 0.02% Pluronic acid F-127 
(Invitrogen). After incubation, cells were washed gently and 
resuspended in RPMI containing 0.1% BSA and incubated for 
10 min at 37°C. Cells were then stimulated with anti-CD3 and 
anti-CD28, alternatively with PMA and ionomycin. Immediately 
after addition of the stimulus, Fluo-3/Fura-Red ratio as a measure 
of the released cytosolic Ca2+ concentration was monitored by 
FACS analysis. The quantification of the measurements was ana-
lyzed using FlowJo software (Tree Star, USA). For T lymphocytes 
stimulated with anti-CD3 and anti-CD28, [Ca2+]i was calculated 
from the equation: [Ca2+]i  =  Kd  ×  Sf380/b380 (R–Rmin)/
(Rmax–R), where Kd is 224 nm in the cytoplasmic environment; 
Sf380/b380 is the ratio of the intensities of the free and bound 
dye forms at 380 nm; R is the fluorescence ratio (340/380 nm) 
of the intracellular Fura-2; Rmax and Rmin are the maximal and 
minimal fluorescence ratios obtained by addition of Digitoxin 
and EGTA (final concentration 3 mmol/l), respectively.
chromatin immunoprecipitation (chiP)
The 3–4 × 106 splenic CD3+ T-cells from CREMα tg and WT mice 
were stimulated for 45 min for CREM binding or 4 h for Histon 
4 acetylation using Phorbol-12-myristat-13-acetat (30 nM) and 
ionomycin (1.5 µM) (both Sigma-Aldrich, USA) or left unstimu-
lated. T-cells were cross-linked with 1% formaldehyde (Merck, 
Germany) for 5 min, washed, lysed, and sonicated. Supernatants 
were diluted in RIPA buffer. A proportion (10%) of the diluted 
supernatants was kept as input (PCR amplification of the total 
sample). For each immunoprecipitation reaction, an equal DNA 
amount was used. Samples were immunoprecipitated with 
0.6–3 µg antibody (anti-CREM 2 µg; anti-NFAT 3 µg, both Abcam, 
UK; anti-Histon H4 Acetyl-K8 0.6 µg, Epitomics, USA) or with its 
isotype control (mouse monoclonal IgG1 or rabbit polyclonal IgG, 
both Abcam, UK) at 4°C overnight. Protein G Dynabeads (Novex 
by Life technologies, Germany) were incubated with the samples 
for 4 h at 4°C. Protein–DNA beads complexes were washed strin-
gently with wash buffer (X-ChIP protocol from Abcam). Protein–
DNA complexes were eluted in 1% SDS, 100 mM NaHCO3 for 
15 min at 30°C, and reverse-cross-linked at 65°C overnight. For 
protein digestion, Proteinase K (20 mg/ml) was added to the sam-
ples and incubated for 2 h at 54°C. DNA was recovered using the 
Wizard kit (Promega, Germany) and subjected to PCR analysis on 
an ABI prism 7300 real-time PCR system. Primer sequences used 
for real-time PCR for the CREM-binding site or H4-acetylation 
of the IL-21 promoter were 5′-GAAAACTGGAATTCACCCA 
TGTCTCTCTT-3′ and 5′-AGAAGAGGCCAAGCCCTCCC 
ATTG-3′. The immunoprecipitated DNA was calculated as 
relative to the respective input DNA. For H4-acetylation, the 
percent of input of the stimulated immunoprecipitated DNA was 
calculated as n-fold to the respective unstimulated DNA. Primer 
sequences used for the putative CREM-binding site of the CD3ζ 
chain promoter were 5′-CTGAATTGAGGCCAAGTTCAGA-3′ 
and 5′-AAGCATATATCT AAGTTGCTGTGTGG-3′. The 
immunoprecipitated CREMα tg DNA was calculated as n-fold to 
the respective WT DNA.
reporter-chiP (r-chiP)
Reporter ChIP technique enables the study of the in vivo binding 
of transcription factors to a specific binding site on a promoter 
of a reporter construct (33). To analyze CREM binding to the 
mutated or not-mutated Il-21-luc promoter, 5 Mio EL-4 culture 
cells were spread in six-well plates in 3 ml RPMI + 5% FCS (with-
out P/S) and left to rest for 2 h at 37°C. EL-4 cells were transfected 
with 6 µg Il-21-luc promoter plasmid Il-21-luc promoter mutated 
plasmid and K2 transfection reagent overnight. Cells were split 
the next day and incubated for 4 h with PMA (20 nM) and iono-
mycin (2 µM) or left unstimulated. After 4 h, cells were harvested 
for R-ChIP and analyzed for CREM binding as described above.
Plasmid construction and Mutagenesis
The 267-bb IL-21 promoter region (25) was amplified by PCR 
from genomic DNA of FVB WT mice using Q5 Hot Start High-
Fidelity DNA Polymerase (NEB, USA) and cloned into KpnI 
and BglII sites of the pGL3 plasmid (Promega, USA) to gener-
ate the Il-21-luc construct. Oligonucleotides used for genomic 
PCR were 5′-GCAGATCTGATGACAGGGCCTTGGTCTG-3′ 
and 5′-ACGGTACCTCAGACAAA CCAGGTGAGGTG-3′. 
Mutagenesis of the half-CRE site within the Il-21-luc plasmid 
was performed with the Q5 Site-Directed Mutagenesis Kit (NEB, 
USA) according to manufacturer’s instructions. Oligonucleotides 
used for mutagenesis of the half-CRE site cagt into ccgg 
were 5′-CTTCAACCTGccggTGCACAGGTTGTCG-3′ and 
5′-TGAGAACCAGACCAAGGTG-3′.
luciferase reporter gene assays
EL-4 cells were transfected with the K2 Transfection System 
(Biontex, Germany) by using 1 × 106 cells and a total of 1.5 µg 
of indicated reporter plasmids and expression plasmids or 
pcDNA according to manufacturer’s instructions. Whenever an 
effector:reporter co-transfection was performed, the molar ratio 
between the two was 3:1. Before transfection cells were incubated 
with 20  µl/ml Multiplayer (K2 Transfection System) for 2  h at 
37°C. All cells were co-transfected with 0.5 µg of Renilla lucif-
erase promoter plasmid (pRL-TK) as a normalization control for 
transfection efficiency. Cells were left to rest over night before 
luciferase activity was measured by using the Dual-Glo Luciferase 
Assay System (Promega, USA). For experiments with cyclosporin 
A (CSA), transfected cells were incubated with or without 1 µg/
ml CSA for 1 h and stimulated with PMA (20 nM) and ionomycin 
(2µM) for 5 h before luciferase activity was measured. Expression 
plasmid NFATc2 was a kind gift from Tobias Bopp (University 
of Mainz, Institute of Immunology) and the expression plasmid 
CREMα was a kind gift from Dr. P. Sassone-Corsi (University of 
California, Irvine, CA, USA).
induction of colitis
Acute dextran sodium sulfate (DSS) colitis was induced by 
giving mice 3.5% (w/v) DSS (molecular mass, 36–50  kDa; MP 
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Biomedicals, USA) in drinking water ad libitum for 6 days. Body 
weight and fecal status were followed daily from the time of colitis 
induction. Mice were killed on day 6 when some of the animals 
had lost more than 15% of their initial body weight. Spleen, mes-
enterial, and peripheral lymph nodes were harvested for further 
analysis. The biggest part of the colon was fixed in formalin, and 
the other small part was washed with PBS and frozen in RNA later 
(Qiagen, Germany) for mRNA analysis.
immunization
For T cell-dependent immunization, groups of age-matched mice 
were immunized i.p. with 100 µg 4-hydroxy-3-nitrophenylacetyl 
chicken gamma globulin (NP-CGG) (Biosearch Technologies, 
USA) in Imject Alum (Thermoscientific, USA). Spleens were 
harvested 7 days later.
histological scoring
Four micrometers of paraffin sections from the fixed colon were 
serially cut, mounted onto glass slides, and deparaffinized. The 
colon sections were stained with hematoxylin and eosin (H&E) 
by the Core Facility (IZKF) of the RWTH Aachen University. 
Blinded histological scoring was performed using a standard 
microscope, based on The Jackson Laboratory Scoring (TJL) 
method, as described previously (34, 35). Each colon section 
was scored for the four general criteria: severity, degree of 
hyperplasia, degree of ulceration, if present, and percentage of 
area involved. A subjective range of 1–3 (1 = mild, 2 = moder-
ate, 3 = severe) was used for the first three categories. Severity: 
focally small or widely separated multifocal areas of inflamma-
tion limited to the lamina propria were graded as mild lesions 
(1). Multifocal or locally extensive areas of inflammation 
extending to the submucosa were graded as moderate lesions 
(2). If the inflammation extended to all layers of the intestinal 
wall or the entire intestinal epithelium was destroyed, lesions 
were graded as severe (3). Hyperplasia: mild hyperplasia 
consisted of morphologically normal lining epithelium that 
was two or more times thicker (length of crypts) than adjacent 
or control mucosa. Moderate hyperplasia was characterized 
by the lining epithelium being two or three times normal 
thickness, cells were hyperchromatic, numbers of goblet cells 
were decreased, and scattered individual crypts developed 
an arborizing pattern. Severe hyperplastic regions exhibited 
markedly thickened epithelium (four or more times normal), 
marked hyperchromasia of cells, few to no goblet cells, a high 
mitotic index of cells within the crypts, and numerous crypts 
with arborizing pattern. Ulceration was graded as: 0 = no ulcer, 
1 = 1–2 ulcers (involving up to a total of 20 crypts), 2 = 1–4 
ulcers (involving a total of 20–40 crypts), and 3 =  any ulcers 
that exceed the previous. A 10% scale was used to estimate the 
area involved in the inflammatory process: 0 = 0%, 1 = 10–30%, 
2 = 40–70%, 3 = >70%.
Flow cytometric analysis
For surface staining, single-cell suspensions were isolated from 
spleens and mesenterial lymph nodes (mLNs) after 6  days of 
colitis induction and stained with anti CD4-FITC (eBioscience, 
USA) and anti CD4-APC (BD Bioscience, Germany). For meas-
urement of intracellular cytokines, cells were treated with P/I 
and GolgiPlug (BD) for 5  h and fixed and permeabilized with 
FoxP3 staining buffer set (eBioscience) following the manufac-
turers’s instructions. Intracellular cytokines were stained with 
anti-IL-21-Alexa 647 (eBioscience) and anti IL-17-Alexa 488 
(BD) antibodies. Intracellular staining of CD3ζ was performed 
using Cytofix/Cytoperm Kit (BD) and anti CD3ζ-PE antibody 
(BD) according to the manufacturer’s instructions. Samples were 
analyzed using a FACS Canto II (BD) and data analyzed using 
FCS Express (De Novo Software) software.
rna isolation and real-time Pcr
Total RNA from cells of mLN, inguinal lymph nodes, and colon 
tissue after DSS treatment was isolated using RNeasy Mini Kit 
(Qiagen, Germany). cDNA was then generated from 700 ng total 
RNA using RevertAid H Minus First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific, USA) according to the manufacturer’s 
instructions. Real-time PCR was performed using SYBR Green 
PCR kit (Eurogentec, Germany) and data were acquired with the 
ABI prism 7300 real-time PCR system (Applied Biosystems by Life 
Technologies, Germany). Each measurement was set up in dupli-
cates, and two independent experiments were performed. After 
normalization to endogenous housekeeping control gene β-Actin 
for mice, the relative expression was calculated. The following prim-
ers were used: 5′-AAGATTCCTGAGGATCCGAGAAG-3′ and 
5′-GCATTCGTGAGCGTCTATAGTGTC-3′ for IL-21 [adapted 
from Ref. (36)] 5′-AGCTGGACCACCACATGAATT-3′ and 
5′-CCACACCCACCAGCATCTTC-3′ for IL-17; 5′-CCAGTGT 
GAAGATGGTTGTGACC-3′ and 5′-GGTGCTTATAAAAA 
GCCAGACCTTG-3′ for IL-23; 5′-TGCCAAGTTTGAGGT 
CAACAACCCA-3′ and 5′-CCCACCCCGAATCAGCAGCG-3′ 
for IFN-γ; 5′-ACTATTGGCAACGAGCGGTTC-3′ and 5′-TTA 
CGGATGTCAACGTCACACTTC-3′ for β-Actin. mRNA 
expression levels of IL-21 in mLNs were compared to IL-21 mRNA 
expression levels in peripheral lymph nodes (n-fold). mRNA 
expression levels of IL-21, IL-17, IL-23, and IFN-γ in colon tissue 
of CREMα tg mice were compared to the their respective mRNA 
expression levels of their untreated WT littermates (n-fold).
mRNA expression of the CD3ζ chain was determined in CD4 
positive T cells extracted by MACS isolation with the following 
primers: 5′-ATTGTAGAGCTGGTTGGGGTCCTG-3′ and 
5′-CATCCTCCACGTGCGGTTCC-3′. n-fold of CD3ζ chain 
mRNA expression in CREMα tg mice was calculated to the CD3ζ 
chain mRNA expression of their WT littermates.
Expression of cMAF, Bcl-6, and IRF4 was determined in 
isolated T cells, which were stimulated with P/I for 6  h or 
left unstimulated. The following primers were used: 5′-GCC 
CAA CAA GCT AGA AAG-3′ and 5′-TCT CTG AGG GTC 
TGG AAA CT-3′ for IRF4; 5′-AGG GAC CTG TTC ACG 
AGA TTA TTG-3′ and GTC CCC GAC CAA GCT CAG 
T for Bcl-6; 5′-AGCAGTTGGTGACCATGTCG-3′ and 
5′-TGGAGATCTCCTGCTTGAGG-3′ for cMAF.
statistical analysis
All data are presented as mean ± SEM. Differences between two 
groups were evaluated using unpaired or paired, when necessary, 
FigUre 1 | caMP-responsive element modulator alpha overexpressing T cells produce enhanced levels of il-21. (a) Percentages of IL-21+ cells within 
CD3+ T cells in spleens of untreated mice or mice after immunization with NP-CGG/Alum. Data show mean percentage ± SEM, *p < 0.05. (B) Representative flow 
cytometric dot plots of IL-21 expressing CD3+ T-cells in a CD3+-Gate.
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two-sided (or one-sided, where specifically indicated) Student’s 
t-test when data were normally distributed. Otherwise, a non-
parametric Mann–Whitney test was performed. All statistical 
analysis and subsequent graphics generations were performed 
using GraphPad Prism version 5.0 (GraphPad Software, USA). 
A p-Value <0.05 was considered significant.
resUlTs
creMα enhances il-21 Production  
in T cells
Previously, we have shown that mice with a T cell-specific over-
expression of CREMα show an enhanced IL-21 production both 
in  vitro after T cell stimulation with anti-CD3 and anti-CD28 
and in vivo in a contact dermatitis model (7). To further confirm 
that CREMα regulates IL-21 expression, we immunized WT and 
CREMα transgenic (CREMα tg) mice with the T cell-dependent 
antigen NP-CGG. Untreated CREMα tg mice already showed a 
higher frequency of IL-21 producing cells within the CD4+ T cell 
population (Figures 1A,B). Seven days after immunization IL-21 
production was enhanced in WT and CREMα tg mice compared 
to untreated mice but to higher extent in CREMα tg mice 
(Figures  1A,B). These data confirm our previously published 
observation that CREMα enhances IL-21 expression both in vitro 
and in vivo.
creMα suppresses cD3ζ chain 
expression resulting in enhanced 
calcium influx
IL-21 expression depends on increased intracellular calcium 
(Ca2+) levels which activate NFAT that in turn activates Il21 
gene transcription (23). Accordingly, we evaluated Ca2+ 
responses in both WT and CREMα tg T cells. Compared to 
WT T cells, we noted an enhanced-free intracytoplasmic 
Ca2+ response in CREMα tg T cells that had been stimulated 
with anti-CD3/CD28 antibodies (Figure  2A). No difference 
was found in T cells that had been stimulated with PMA and 
ionomycin (Figure S1A in Supplementary Material) suggesting 
that this difference is related to alterations in the CD3 complex. 
Interestingly, both enhanced Ca2+ signaling and NFAT activity 
have been reported in T cells of SLE patients (37, 38). Enhanced 
calcium influx is observed in SLE T cells as well and was linked 
to a decreased expression of the CD3ζ chain (38). In detail, 
reduced CD3ζ chain expression in human SLE T cells results 
in enhanced calcium signaling and vice  versa transfection of 
SLE T cells with the ζ chain construct corrected the heightened 
calcium response in SLE T cells (39). Previously, we have shown 
that CREMα binds to the human CD3ζ chain promoter and 
represses its activity (40). Accordingly, we checked expres-
sion of the CD3ζ chain and found it decreased in both CD4+ 
and CD8+ T cells of CREMα tg animals compared to WT 
animals on protein (Figures 2B,C) as well as on mRNA level 
(Figure  2D), whereas the overall expression of CD3 was not 
altered (Figure S1B in Supplementary Material). Moreover, 
we screened the murine CD3ζ chain promoter for CRE sites 
and identified a putative-binding site of CREMα within this 
promoter. Congruent to the CRE site within the human CD3 
promoter, which we already showed to be regulated by CREMα, 
the identified CRE site in the murine CD3ζ chain promoter is 
located about 390 bp upstream of the transcription start. ChIP 
experiments using an anti-CREM antibody confirmed an up to 
twofold binding of CREMα to this promoter (Figure 2E). Thus, 
the transgenic overexpression of CREMα in T cells probably 
results in a decreased CD3ζ chain expression, thereby causing 
an enhanced Ca2+ influx, which may be responsible for the 
enhanced Il-21 transcription.
FigUre 2 | caMP-responsive element modulator alpha (creMα) represses expression of cD3ζ chain, which leads to enhanced calcium influx. (a) 
Pan-T cells were isolated via MACS isolation from CD2-CREMα TG mice and appropriate wild-type (WT) mice. Ca2+ influx was measured immediately after 
stimulation with anti-CD3 and anti-CD28. The picture shows a typical experiment (n = 4). (B) CD3ζ chain expression was measured in CD3+ T cells of CREMα 
transgenic and WT mice by flow cytometry. (c) The picture shows a typical histogram of CD3ζ chain expression in CD3+ (left), CD3+CD4+ (middle), and CD3+CD8+ T 
cells (right). (D) CD4 positive T cells were extracted by MACS isolation and mRNA expression of the CD3ζ chain was determined (n = 3, *p < 0.05). (e) Binding of 
CREM to the CD3ζ promoter was determined by chromatin immunoprecipitation assay in unstimulated splenocytes of CREMα transgenic and WT mice (n = 4, 
***p < 0.005).
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creM Binds to and activates the Proximal 
il-21 Promoter region
We next stimulated splenic T cells from WT and CREMα tg mice 
in vitro either with anti-CD3/CD28 antibodies or with Phorbol-
12-myristat-13-acetate and ionomycin (P/I) and analyzed Il-21 
mRNA expression (Figure  3A). As expected, stimulation with 
anti-CD3/CD28 antibodies significantly upregulated Il-21 
expression of CREMα tg T cells. However, stimulation with 
P/I resulted in a much higher and significant induction of Il-
21 mRNA expression in both WT and CREMα tg T cells. This 
implies that the IL-21 expression in CREMα tg T cells might in 
part be due to a low CD3ζ expression, but that pathways down-
stream of the TCR signaling complex must also be involved, since 
P/I acts independently from the CD3ζ complex. However, NFAT 
binding was insignificantly enhanced in CREMα transgenic T 
cells after stimulation (Figure  3B), which on the other hand 
suggests that calcium/NFATc2-dependent mechanism at least 
partially influence IL-21 transcription in CREMα tg T cells. 
Stimulation of WT and CREMα tg T cells with P/I resulted in 
enhanced acetylation on histone 4 of the IL-21 promoter in com-
parable manner (Figure  3C), which means that CREMα does 
not change acetylation of histone 4. We, furthermore, did not 
detect differential expression of c-Maf, IRF4, and Bcl-6, which 
are known to be associated with IL-21 induction (Figure S2 in 
Supplementary Material) (41–43). We, therefore, assumed that 
CREMα might also directly regulate IL-21 expression itself. To 
determine whether Il-21 was a direct target of the transcrip-
tion factor CREMα, the Il-21 promoter sequence was screened 
FigUre 3 | caMP-responsive element modulator alpha (creMα) binds to and directly activates the proximal il-21 promoter region.  
(Continued)
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for potential CRE-binding sites. Mehta et al. already identified 
and characterized a murine IL-21 proximal promoter region, 
which is located immediately 5′of the first coding exon. This 
region is highly conserved between men and mice and activates 
IL-21 transcription (25). This region also contains a binding 
site matching a consensus half-site for CREM (half CRE-site) 
(a) Splenic CD4+ T cells from CD2-CREMα transgenic (tg) mice and their wild-type (WT) littermates were stimulated with anti-CD3/CD28 antibodies or P/I for 12 h, 
mRNA was isolated from these cells, and measured for IL-21 cytokine expression compared to appropriate unstimulated cells (n = 4, *p < 0.05). (B) Splenic CD3+ 
T cells from CD2-CREMα tg mice and their WT littermates were stimulated with P/I for 4 h and chromatin immunoprecipitation (ChIP) assay was performed with 
anti-NFAT (n = 3). (c) Splenic CD3+ T cells from CD2-CREMα tg mice and their WT littermates were stimulated with P/I for 4 h, and ChIP assay was performed with 
anti-H4 Acetyl-K8 antibody (n = 4, one-sided, paired t-test *p < 0.05). (D) Genomic sequence of the murine IL-21 promoter region with the indicated CREM-binding 
half CRE site cagt within the promoter. (e) CD3+ T-cells were isolated from spleens of CREMα tg mice and appropriate WT mice and stimulated with P/I for 45 min 
or left unstimulated. Binding of CREM to the IL-21 promoter was determined by ChIP assays (n = 6, *p < 0.05). (F) EL-4 cells were transfected with either IL-21-luc 
or IL-21-luc with a mutated half-CRE site and either an empty control vector (pcDNA) or a plasmid-expressing CREMα. CREM binding was assessed by reporter-
ChIP (n = 4, *p < 0.05). (g) EL-4 cells were transfected with either IL-21-luc or IL-21-luc with a mutated half-CRE site and either an empty control vector (pcDNA) 
alone, or plasmid expressing NFATc2 or CREMα. Cells were left to rest over night before luciferase activity was measured. Activity is expressed as the fold induction 
in luciferase activity relative to IL-21 pro-luc reporter activity cotransfected with pcDNA and is adjusted for transfection efficiency with a co-transfected Renilla 
luciferase promoter plasmid (pRL-TK) (n = 4, *p < 0.05, ***p < 0.005). (h) EL-4 cells were transfected with IL-21-luc and either an empty control vector (pcDNA), or 
plasmid-expressing NFATc2 or CREMα. Cells were stimulated with P/I in the presence or absence of cyclosporin A and luciferase activity was measured (n = 3, 
***p < 0.001).
FigUre 3 | continued.
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(Figure 3D). We next sought to confirm CREM binding to the 
Il-21 promoter in  vivo using ChIP assays with murine splenic 
CD3+ T cells. CREM binding to the proximal IL-21 promoter 
region was enhanced in WT T cells as well as in CREMα tg T cells 
after stimulation with P/I; however, we did not find a significant 
difference in binding between CREMα tg T cells and WT T cells 
(Figure 3E). To identify if the site is indeed important for bind-
ing of CREM, we used the R-ChIP technique, which we recently 
established and which enables the study of the in vivo binding 
of transcription factors to a specific binding site on a promoter 
of a reporter construct. Using this technique, we could show a 
specific binding of CREM to this CRE site. Transfection of EL-4 
cells with a IL-21 promoter construct spanning 267  bp of the 
Il-21 promoter (Il-21-luc) containing a mutated CRE site almost 
abolished CREM binding after stimulation compared to the non-
mutated IL-21 promoter plasmid (Figure 3F). To further test the 
specific function of the CREM-binding site in the Il-21 promoter, 
we used the abovementioned luciferase construct (Il-21-luc). 
We transfected EL-4 T cells with the Il-21-luc reporter plasmid 
including co-transfection of expression plasmids for CREMα or 
NFATc2 and measured luciferase activity compared to an empty 
control vector (pcDNA) (Figure  3F). NFATc2 plasmid served 
as a control in our setting as activation of IL-21 transcription 
by NFATc2 is well known (23, 25). Consequently, NFATc2-
transfected cells revealed an about 20-fold increased IL-21-luc 
activity compared to cells transfected with pcDNA. Transfection 
with Il-21-luc and an expression vector for CREMα led to an about 
twofold-enhanced Il-21-luc activity compared to co-transfection 
with pcDNA suggesting that CREMα is at least partially respon-
sible for the activity of the Il-21 promoter. The mutagenesis of the 
half-CRE site prevented upregulation of Il-21-luc activity in the 
presence of exogenous CREMα (Figure 3G), which is in accord-
ance with the reduced binding shown by R-ChIP in Figure 3F. 
However, promoter activity was also reduced in the presence of 
exogenous NFATc2. This somehow unexpected finding probably 
results from chromatin remodeling or CREM/NFAT interactions 
suggesting crucial importance of this site for the whole promoter 
activity. To further dissect the direct and Ca2+-mediated effects 
of CREMα on IL-21 expression, we evaluated the luciferase 
activity of cells transfected with IL-21-luc and CREM or NFATc2 
plasmids in the presence of CSA. CSA is an immunosuppressive 
drug and inhibits calcineurin that, in turn, results in the block-
ade of the transcription factor NFATc2 (44). As a consequence, 
NFATc2-mediated Il-21-luc activity was abrogated in stimulated 
cells in the presence of CSA. However, CREM-mediated Il-21-luc 
activity was not altered by CSA (Figure 3H). These data show that 
the direct effect of CREMα on IL21 promoter activity is mediated 
independently of NFATc2. We conclude from these experiments 
that CREMα directly binds to the proximal Il-21 promoter and 
thereby activates IL-21 transcription.
creMα Transgenic Mice Display 
enhanced Disease activity in  
Dss-induced colitis
IL-21 supports generation and stabilization of pathogenic Th17 
cells (13, 29), which might be one of the mechanisms by which 
IL-21 expands and sustains ongoing mucosal inflammation. 
IL-17 expression in CREMα tg mice is probably to some extent 
regulated by IL-21, as was shown by blockade experiments with 
IL-21RFc, which prevented RORyt and IL-17 expression in vitro 
(7). We next asked how CREMα tg T cells affect disease activity 
and cytokine release in a murine colitis model. We, therefore, 
used an established murine model of colitis, in which colitis is 
induced by oral administration of DSS. Wild-type and CREMα 
tg mice were given 3.5% DSS in their drinking water. While 
CREMα tg mice suffered from a progressive weight loss, WT 
mice hardly lost weight (Figure 4A). Histological changes fol-
lowing DSS treatment were detectable in both groups, but the 
extent of tissue damage was greater in CREMα tg mice com-
pared to WT mice (Figures 4B,C). We conclude from this that 
overexpression of CREMα in T cells enhances inflammation in 
DSS-induced colitis.
colitis in creMα tg Mice is accompanied 
by higher local il-21 expression
To further analyze if higher disease activity also involves higher 
expression of IL-21 and IL-17, we analyzed IL-21 protein expres-
sion by flow cytometry in spleen and mLNs of colitic mice. 
CREMα tg mice showed enhanced T cellular IL-21 production 
in mLN (Figure 5A) and spleen (Figure 5B) compared to WT 
FigUre 4 | caMP-responsive element modulator alpha (creMα) transgenic mice display enhanced disease activity in dextran sodium sulfate 
(Dss)-induced acute colitis. (a) Percentage of body weight loss of CD2-CREMα transgenic (tg) and wild-type (WT) mice measured daily for a period of 6 days 
after colitis induction with DSS (n = 12 animals each, **p < 0.01). (B) Results of histological scoring of colon sections from CD2-CREMα tg and WT mice on day 6 
after DSS treatment (n = 12, **p < 0.01). (c) Representative photomicrographs of hematoxylin and eosin-stained colon sections from CD2-CREMα tg (right) and WT 
(left) mice at day 6 of acute DSS colitis imaged using a 10× objective (scale bar = 100 µm).
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animals. Additionally, mRNA levels of Il-21 were also enhanced 
in mLN (Figure 5C) of CREMα tg mice compared to WT mice 
and colon tissue also showed enhanced Il-21 mRNA expression 
(Figure 5D), while there was an insignificant tendency toward 
enhanced IL-17 transcription (Figure 5E). IL-23 (Figure 5F) and 
IFN-γ expression was not altered between both groups neither 
on mRNA (Figure 5G) nor on protein level (not shown). IL-17+ 
T cells were not enhanced in mLN (Figure 5H) from CREMα 
tg mice, but significantly enhanced in spleens (Figure 5I). These 
data proof enhanced production of the inflammatory cytokine 
IL-21 in CREMα tg colitic mice, which potentially accounts for 
accelerated disease activity.
DiscUssiOn
In this work, we describe the role of CREMα for the tran-
scriptional activity of the Il-21 promoter. We analyzed two 
mechanisms that might account for the enhanced IL-21 pro-
duction in CREMα tg mice. First, CREMα binds to the CD3ζ 
chain promoter resulting in a downregulation of CD3ζ chain 
expression. This mechanism has been observed in SLE patients 
before which display enhanced T cellular levels of CREMα (40). 
Downregulation of the CD3ζ complex results in altered lipid 
raft formation, lower excitation threshold, and enhanced Ca2+ 
signaling (45). In analogy to the human disease, we also found 
enhanced Ca2+ signaling in T cells of the CREMα tg mice. Ca2+ 
is central for IL-21 transcription, since it activates NFAT, which 
is the most important transcription factor for activation of the 
IL-21 promoter (23). Nevertheless, apart from this we also found 
a striking upregulation of Il-21 transcription in CREMα tg T 
cells by P/I stimulation, which suggest a mechanism independ-
ent from the T cell receptor. We thus screened the murine Il-21 
promoter and identified a CRE-halfside, which is crucial for the 
whole promoter activity and is able to bind CREMα and most 
probably accounts for transcriptional activation mediated by 
this transcription factor. This is supported by two experiments; 
first, R-ChIP shows abrogated binding of CREM on the mutated 
CRE-site, second, calcineurin treatment does not affect activity 
of CREM on the IL-21 promoter, which both suggest NFAT-
independent effects. Thus, in analogy to the murine and human 
IL-17 promoter, CREMα also displays activator function for this 
proinflammatory cytokine (Figure  6). This could have several 
implications. We have shown before that blockade of IL-21 by 
an IL21RFc fragment downregulates IL-17 production in the 
FigUre 5 | colitis in caMP-responsive element modulator alpha (creMα) transgenic (tg) mice is accompanied by higher local il-21 expression.  
(a) Percentages of IL-21 expressing CD4+ T-cells in mesenterial lymph node (mLN) and (B) in spleen of age-matched CREMα tg mice and appropriate wild-type 
(WT) mice after 6 days of colitis induction measured by flow cytometry. Data show mean percentage ± SEM of IL-21 expressing CD4+ T-cells in at least four mice 
per group (*p < 0.05). Representative flow cytometric dot plots of IL-21-expressing CD4+ T-cells in a CD4+-gate on the right. (c) mRNA levels of IL-21 in mLN cells 
(n-fold compared to IL-21 mRNA in peripheral LN) of CREMα tg mice compared to their WT littermates after 6 days of colitis induction measured by real-time 
quantitative PCR (n = 4, *p < 0.05). (D) mRNA levels of IL-21 in colon tissue of CREMα tg mice and appropriate WT mice after 6 days of dextran sodium sulfate 
(DSS) treatment compared to their untreated WT controls (n-fold) measured by real-time quantitative PCR (n = 4, *p < 0.05). (e) mRNA levels of IL-17, (F) IL-23, 
and (g) IFN-γ in colon tissue of CREMα tg mice and appropriate WT mice after 6 days of DSS treatment compared to their untreated WT controls (n-fold) measured 
by real-time quantitative PCR (n = 4–5). (h) Percentages of IL-17-expressing CD4+ T-cells in mLN and (i) in spleen of age-matched CREMα tg mice and appropriate 
WT mice after 6 days of colitis induction measured by flow cytometry. Data show mean percentage ± SEM of IL-17-expressing CD4+ T-cells in at least four mice per 
group (**p < 0.01). Representative flow cytometric dot plots of IL-17-expressing CD4+ T-cells in a CD4+-gate on the right.
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FigUre 6 | Model of il-21 induction by caMP-responsive element modulator alpha (creMα). CREMα represses CD3ζ chain expression. CD3ζ chain, 
which normally transduces TCR signals into the cell, can be replaced by FcRγ. FcRγ signals much stronger than the CD3ζ chain. Therefore, higher amounts of Ca2+ 
are released, which lead to an enhanced binding of NFATc2 to the IL-21 promoter and subsequently induces IL-21 expression. At the same time, CREMα also binds 
to the half-CRE site in the IL-21 promoter, which is only part due to the low CD3ζ expression as pathways downstream of the TCR complex signaling must be also 
involved. CREMα likewise binds to the IL-17 promoter and increases IL-17 expression while IL-21, to some extent, supports generation and stabilization of the IL-17 
expression.
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CREMα tg T cells in vitro (7), which underpins the importance of 
CREM-mediated IL-21 transcription for pathogenic IL-17 pro-
duction. In addition, IL-21 is a central cytokine for promotion 
of B cell antibody production. Fas (CD95)−/− CREMα tg mice 
display enhanced anti-dsDNA autoantibodies and enhanced 
total IgG production (7, 8), which could possibly be related to 
this fact. Transcription of CREM itself is dependent on calcium/
calmodulin-dependent protein kinase type IV (CamKIV) activa-
tion (46). Pharmacologic inhibition of CamKIV by the inhibitor 
KN93 or genetic inhibition of CamKIV decreases frequency of 
IL-17 producing cells and efficiently decreases lupus-like disease 
in murine models and ameliorates experimental autoimmune 
encephalomyelitis (47, 48).
We already demonstrated a pathogenic role for CREMα in 
lupus disease as well as in a model of acute lung injury (7, 49). 
Here, we analyzed CREMα tg T cells and IL-21 expression of 
these T cells within an acute model of murine colitis. Several 
observations indicate that IL-21 can contribute to the detri-
mental response in inflammatory bowel disease-related inflam-
mation. IL-21 is overproduced in inflamed gut of patients with 
inflammatory bowel disease compared to non-inflamed and 
inflamed controls (11, 50). Furthermore, mice lacking IL-21 
are unable to upregulate Th17-associated molecules during 
experimental gut inflammation and are largely protected 
against chemically induced colitis (29, 30). Moreover, WT 
mice, given a neutralizing IL-21R/Fc fusion protein, exhibit 
an amelioration of experimental colitis as compared to control 
mice (29); however, this was not confirmed by our experiments, 
which could be due to strain-specific alterations or due to 
the pharmacologic properties of the molecule. Nevertheless, 
how IL-21 is regulated in inflammatory bowel disease is not 
fully understood. A better understanding of the regulation of 
IL-21 expression in the context of inflammatory disease might 
be helpful in developing novel treatments to control disease 
pathogenesis.
Our data suggest that CREMα might be involved in IL-21 
secretion of T cells in DSS-colitis as was shown before in a contact 
dermatitis model. CREMα expression in T cells from inflamma-
tory bowel disease patients has not been investigated yet, further 
research will show if CREMα expression is elevated within T cells 
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or inflamed tissues of these patients and if the CamKIV inhibitor 
KN-93 might also be of benefit in colitis.
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